Interestingly, mutations in TET2 are somatic (acquired) and commonly found in (1) myeloid malignancies such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML); myeloproliferative neoplasms (MPNs); and (2) lymphoid cancers such as Angioimmunoblastic T-cell lymphoma (AITL) and Peripheral T-cell lymphoma (PTCL). Here, TET2 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.